ELQ-300 Prodrugs for Enhanced Delivery and Single-Dose Cure of Malaria

ELQ-300 is a preclinical candidate that targets the liver and blood stages of Plasmodium falciparum, as well as the forms that are crucial to transmission of disease: gametocytes, zygotes, and ookinetes. A significant obstacle to the clinical development of ELQ-300 is related to its physicochemical...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Antimicrob Agents Chemother
Главные авторы: Miley, Galen P., Pou, Sovitj, Winter, Rolf, Nilsen, Aaron, Li, Yuexin, Kelly, Jane X., Stickles, Allison M., Mather, Michael W., Forquer, Isaac P., Pershing, April M., White, Karen, Shackleford, David, Saunders, Jessica, Chen, Gong, Ting, Li-Min, Kim, Kami, Zakharov, Lev N., Donini, Cristina, Burrows, Jeremy N., Vaidya, Akhil B., Charman, Susan A., Riscoe, Michael K.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society for Microbiology 2015
Предметы:
Experimental Therapeutics
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4538462/
https://ncbi.nlm.nih.gov/pubmed/26124159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01183-15
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы